Subscribe to Journal
Get full journal access for 1 year
only $20.79 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Xu, Z., Pang, T. C. Y., Liu, A. C., Pothula, S. P., Mekapogu A. R., Perera C. J. et al. Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis. Br. J. Cancer https://doi.org/10.1038/s41416-020-0782-1 (2020).
Le Large, T. Y. S., El Hassouni, B., Funel, N., Kok, B., Piersma, S. R., Pham, T. V. et al. Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment. Ther. Adv. Med. Oncol. 11, 1758835919841233 (2019).
Firuzi, O., Che, P. P., El Hassouni, B., Buijs, M., Coppola, S., Lohr, M. et al. Role of c-MET inhibitors in overcoming drug resistance in spheroid models of primary human pancreatic cancer and stellate cells. Cancers (Basel) 11, 638 (2019). https://doi.org/10.3390/cancers11050638.
Tomihara, H., Yamada, D., Eguchi, H., Iwagami, Y., Noda, T., Asaoka, T. et al. MicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiation therapy. Cancer Sci. 108, 398–407 (2017).
Rath, N. & Olson, M. F. Regulation of pancreatic cancer aggressiveness by stromal stiffening. Nat. Med. 22, 462–463 (2016).
Ethics approval and consent to participate
This study did not require ethical approval.
All data generated or analysed during this study are included in this published article.
The authors declare no competing interests.
This work was partially supported by the following grants: Zabawas Foundation—Cancer Center Amsterdam Foundation CCA2019-5-55 (P.S.), CCA2015-1-19 (E.G.), CCA2018-5-48 (E.G.), KWF Dutch Cancer Society—KWF project#11957 (E.G.), and Associazione Italiana per la Ricerca sul Cancro—AIRC/Start-Up grant (E.G.).
Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Che, P.P., Gregori, A., Peters, G.J. et al. Comment on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis. Br J Cancer (2020). https://doi.org/10.1038/s41416-020-1003-7